{"id":{"repo_id":"cornell","oai_identifier":"oai:ecommons.cornell.edu:1813/59083"},"canonical_url":"https://search.ndltd.org/etd/cornell/oai:ecommons.cornell.edu:1813/59083","repository":{"repo_id":"cornell","name":"Cornell University","base_url":"https://ecommons.cornell.edu/server/oai/request"},"display":{"title":"MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER","abstract":"SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.","abstract_html":"SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.","abstract_has_math":false,"creators":["Jing, Hui"],"institution":"Cornell University","degree_name":"Ph. D., Chemistry and Chemical Biology","degree_level":"Doctor of Philosophy","degree_discipline":"Chemistry and Chemical Biology","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":["Lin, Hening"],"committee_members":["Cerione, Richard A.","Weiss, Robert S."],"year":2017,"date_issued":"2017-12-30","date_published":"2017-12-30","updated_at":"2026-11-19T03:20:08Z","subjects":["c-Myc","K-Ras","Lysine fatty acylation","SIRT2","Sirtuin","Chemistry","cancer"],"languages":["en_US"],"rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"rights_urls":["https://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/X4DB800G"],"render_values":[{"text":"https://doi.org/10.7298/X4DB800G","href":"https://doi.org/10.7298/X4DB800G","code":true}]},{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["10474186"],"render_values":[{"text":"10474186","href":null,"code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 10577","ProQuest Publication ID: 10637500"],"render_values":[{"text":"ProQuest Submission ID: 10577","href":null,"code":true},{"text":"ProQuest Publication ID: 10637500","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1813/59083","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1813/59083","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://ecommons.cornell.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aecommons.cornell.edu%3A1813%2F59083","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.chair","label":"Chair","values":["Lin, Hening"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Cerione, Richard A.","Weiss, Robert S."]},{"key":"dc:creator","label":"Author","values":["Jing, Hui"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2018-10-03T19:27:40Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-12-18T07:00:45Z"]},{"key":"dc:date.issued","label":"Date","values":["2017-12-30"]},{"key":"dc:type","label":"Dc Type","values":["dissertation or thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Chemical Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctor of Philosophy"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph. D., Chemistry and Chemical Biology"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Cornell University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["c-Myc","K-Ras","Lysine fatty acylation","SIRT2","Sirtuin","Chemistry","cancer"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial-NoDerivatives 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["https://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["10474186"]},{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/X4DB800G"]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 10577","ProQuest Publication ID: 10637500"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1813/59083"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"cerif:openaire","label":"Cerif Openaire","values":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"492cec32-620a-4ccc-abd0-66f8fb6df55f\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2017-12-30</PublicationDate> <DOI>https://doi.org/10.7298/X4DB800G</DOI> <Authors> <Author> <DisplayName>Jing, Hui</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <License>https://creativecommons.org/licenses/by-nc-nd/4.0/</License> <Keyword>c-Myc</Keyword> <Keyword>K-Ras</Keyword> <Keyword>Lysine fatty acylation</Keyword> <Keyword>SIRT2</Keyword> <Keyword>Sirtuin</Keyword> <Keyword>Chemistry</Keyword> <Keyword>cancer</Keyword> <Abstract>SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"]},{"key":"cris:virtual.author","label":"Cris Virtual Author","values":["Jing, Hui"]},{"key":"cris:virtualsource.collection","label":"Cris Virtualsource Collection","values":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"]},{"key":"dc:description.abstract","label":"Abstract","values":["SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment."]},{"key":"dc:description.collection","label":"Dc Description Collection","values":["Cornell Theses and Dissertations"]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dcterms:license","label":"Dcterms License","values":["https://hdl.handle.net/1813/59810"]},{"key":"dc:title","label":"Title","values":["MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER"]},{"key":"dspace:entity.type","label":"Dspace Entity Type","values":["Publication"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"cerif:openaire":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"492cec32-620a-4ccc-abd0-66f8fb6df55f\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2017-12-30</PublicationDate> <DOI>https://doi.org/10.7298/X4DB800G</DOI> <Authors> <Author> <DisplayName>Jing, Hui</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <License>https://creativecommons.org/licenses/by-nc-nd/4.0/</License> <Keyword>c-Myc</Keyword> <Keyword>K-Ras</Keyword> <Keyword>Lysine fatty acylation</Keyword> <Keyword>SIRT2</Keyword> <Keyword>Sirtuin</Keyword> <Keyword>Chemistry</Keyword> <Keyword>cancer</Keyword> <Abstract>SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"],"cris:virtual.author":["Jing, Hui"],"cris:virtualsource.collection":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"],"dc:contributor.chair":["Lin, Hening"],"dc:contributor.committeemember":["Cerione, Richard A.","Weiss, Robert S."],"dc:creator":["Jing, Hui"],"dc:date.accessioned":["2018-10-03T19:27:40Z"],"dc:date.available":["2019-12-18T07:00:45Z"],"dc:date.issued":["2017-12-30"],"dc:description.abstract":["SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment."],"dc:description.collection":["Cornell Theses and Dissertations"],"dc:format.mimetype":["application/pdf"],"dc:identifier.bibid":["10474186"],"dc:identifier.doi":["https://doi.org/10.7298/X4DB800G"],"dc:identifier.other":["ProQuest Submission ID: 10577","ProQuest Publication ID: 10637500"],"dc:identifier.uri":["https://hdl.handle.net/1813/59083"],"dc:language.iso":["en_US"],"dc:rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"dc:rights.uri":["https://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["c-Myc","K-Ras","Lysine fatty acylation","SIRT2","Sirtuin","Chemistry","cancer"],"dcterms:license":["https://hdl.handle.net/1813/59810"],"dc:title":["MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER"],"dc:type":["dissertation or thesis"],"dspace:entity.type":["Publication"],"others:access_status":["open.access"],"thesis:degree_discipline":["Chemistry and Chemical Biology"],"thesis:degree_level":["Doctor of Philosophy"],"thesis:degree_name":["Ph. D., Chemistry and Chemical Biology"],"thesis:institution_name":["Cornell University"]},"updated_at":"2026-11-19T03:20:08Z"}